TDZD-8

Overview

TDZD-8 is an inhibitor of GSK-3β , with an IC 50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA , and PKC , with all IC 50 s of >100 μM.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Obesity | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > GSK-3

Product Information

• Catalog No.: HY-11012
• CAS No.: 327036-89-5
• Molecular Formula: C10H10N2O2S
• Molecular Weight: 222.26
• Purity: 99.76%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (11.25 mM); Clear solution
• Availability: In-stock

Source

Original product source